Matches in Wikidata for { <http://www.wikidata.org/entity/Q91776070> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q91776070 description "artículu científicu espublizáu n'avientu de 2019" @default.
- Q91776070 description "im Dezember 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91776070 description "scientific article published on 04 December 2019" @default.
- Q91776070 description "wetenschappelijk artikel" @default.
- Q91776070 description "наукова стаття, опублікована 4 грудня 2019" @default.
- Q91776070 name "[In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?]" @default.
- Q91776070 name "[In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?]" @default.
- Q91776070 type Item @default.
- Q91776070 label "[In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?]" @default.
- Q91776070 label "[In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?]" @default.
- Q91776070 prefLabel "[In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?]" @default.
- Q91776070 prefLabel "[In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?]" @default.
- Q91776070 P1433 Q91776070-A8DB0030-B8D1-4FC7-A97D-C1B2F31B7D92 @default.
- Q91776070 P1476 Q91776070-18B6FC81-8B6D-44FB-AF76-4FF726CCBAC9 @default.
- Q91776070 P2093 Q91776070-68B0F19F-24F4-45CE-8ABC-CA110F36711B @default.
- Q91776070 P2093 Q91776070-ACFD89C8-A8B4-4185-91B0-FF296E1D6DAE @default.
- Q91776070 P2093 Q91776070-BB3B565E-50AA-4569-8F0F-35B700176122 @default.
- Q91776070 P2093 Q91776070-E7396CA9-8EEC-4BFD-9A31-4F2B564A2AEE @default.
- Q91776070 P304 Q91776070-479B95D7-D792-4953-8A72-9C86C0FEEA49 @default.
- Q91776070 P31 Q91776070-6A2C6E67-1312-42E1-B388-84B25DE62022 @default.
- Q91776070 P356 Q91776070-0056AC19-42E9-4ACB-979B-7DEF64C698A0 @default.
- Q91776070 P433 Q91776070-886E5AB9-3824-42AF-887F-8AA95773C261 @default.
- Q91776070 P478 Q91776070-BE5E0EE4-F9C2-4103-BD7C-10C44F5584C5 @default.
- Q91776070 P577 Q91776070-BCB2A040-BBF3-4C7F-91C0-471BC93D7C8C @default.
- Q91776070 P698 Q91776070-2B69B969-DC73-4053-BBE9-CD6CEAA98A52 @default.
- Q91776070 P921 Q91776070-2B29E31C-2496-4C5A-B8ED-EE22764BB10A @default.
- Q91776070 P921 Q91776070-54EABEE1-777F-4C17-8937-945028C994A0 @default.
- Q91776070 P356 J.REVMED.2019.11.004 @default.
- Q91776070 P698 31812446 @default.
- Q91776070 P1433 Q3428665 @default.
- Q91776070 P1476 "[In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?]" @default.
- Q91776070 P2093 "G Huard" @default.
- Q91776070 P2093 "L Lanthier" @default.
- Q91776070 P2093 "M Cauchon" @default.
- Q91776070 P2093 "M-É Plourde" @default.
- Q91776070 P304 "67-68" @default.
- Q91776070 P31 Q13442814 @default.
- Q91776070 P356 "10.1016/J.REVMED.2019.11.004" @default.
- Q91776070 P433 "1" @default.
- Q91776070 P478 "41" @default.
- Q91776070 P577 "2019-12-04T00:00:00Z" @default.
- Q91776070 P698 "31812446" @default.
- Q91776070 P921 Q1129105 @default.
- Q91776070 P921 Q3025883 @default.